Skip to content

Individualized Diabetes Education Assisted by CGM (IDEA-CGM)

Individualized Diabetes Education Assisted by CGM (IDEA-CGM)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06784375
Enrollment
72
Registered
2025-01-20
Start date
2025-07-14
Completion date
2027-09-15
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 Diabetes, Nutrition, CGM

Brief summary

This project will compare medical nutrition therapy personalized by continuous glucose monitor (CGM) feedback to control interventions in participants with type 2 diabetes mellitus (T2DM).

Interventions

BEHAVIORALUnblinded CGM/Nutrition Therapy

Personalized nutrition counseling based on CGM data

BEHAVIORALBlinded CGM/Nutrition Therapy

Standard nutrition education which does not incorporate CGM data

BEHAVIORALUnblinded CGM/No Nutrition Therapy

CGM and general diabetes education (no nutrition education)

BEHAVIORALBlinded CGM/No Nutrition Therapy

General diabetes education (no nutrition education)

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective Randomized Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* at least 18 years of age * previous diagnosis of T2DM * HbA1c of 6.8-8.5%

Exclusion criteria

* type 1 diabetes mellitus * treatment with insulin, sulfonylurea, or meglitinide * use of nondiabetic medications that affect blood glucose control (such as corticosteroids) * BMI \<25 kg/m2 or \<23 kg/m2 for participants who self-identify as Asian * weight change \>5 pounds in the 3 months prior to study enrollment * estimated glomerular filtration rate \<60 ml/minute/1.73 m2 * pregnancy or immediate plans to become pregnant 8) breastfeeding 9) anemia (which would affect measurement of HbA1c) 10) changes to glucose lowering medications, including change in dose, in the 3 months prior to enrollment 11) presence of any disease that would make adherence to the protocol difficult."

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin A1c12 weeksMeasure of blood glucose control

Countries

United States

Contacts

CONTACTAnne Bantle
bant0015@umn.edu612-625-8673
PRINCIPAL_INVESTIGATORAnne Bantle

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026